When was Gradian founded?

Gradian was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Gradian located?

Gradian is headquartered in Austria.

Is Gradian a funded company?

Gradian is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Dec 23, 2020.

When was the latest funding round of Gradian?

Gradian's latest funding was a $***** Seed round on Dec 23, 2020, with participation from 0 investor.

Where does Gradian rank among its competitors?

Gradian ranks 207th amongst 343 active competitors, of which 81 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was HaystackAnalytics, which secured $5M in Sep, 2025.

Who are the top competitors of Gradian?

Gradian's top competitors include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Among them, HaystackAnalytics secured the most recent funding round in September, 2025.

Gradian - 2026 Company Profile, Funding & Competitors

Gradian is a seed company based in Austria, founded in 2018. It operates as a Developer of molecular diagnostic devices for the identification of infectious diseases. Gradian has raised $99.2K in funding. The company has 343 active competitors, including 81 funded and 51 that have exited. Its top competitors include companies like Adaptive Biotechnologies, MeMed and HaystackAnalytics.

Company Details

Developer of molecular diagnostic devices for the identification of infectious diseases. The company has developed diagnosis solutions that reduce bacterial contamination.

Website: gradian-dx.com
Email ID: *****@gradian-dx.com

Key Metrics

Founded Year

2018

Location

Austria

Stage

Seed

Total Funding

$99.2K in 1 round

Latest Funding Round

Seed, Dec 23, 2020, $*****

Ranked

207^th among 343 active competitors

Similar Companies

Adaptive Biotechnologies & 409 more

View Gradian's full profile

Gradian has raised a total funding of $99.2K over 1 round.

Here is the list of recent funding rounds of Gradian:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 23, 2020	5035717	Seed	9563028	8549522	2504509	2934450

Access funding benchmarks and valuations. Sign up today!

View details of Gradian's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gradian include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of Gradian, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	77/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, SINE & 31 others	67/100
4th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	64/100
5th	Seegene Technologies 2000, Seoul (South Korea), Public	Developer of molecular diagnostic kits to detect infectious and genetic diseases	-	IMM Investment, Songhyun Investment & 3 others	59/100
6th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, Balderton Capital & 9 others	58/100
7th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
8th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Google Ventures & 26 others	57/100
9th	Quantamatrix 2010, Seoul (South Korea), Public	Multiplexed platform for disease daignosis	$198K	Treatment Action Group, Partners Investment ... & 6 others	55/100
10th	T2 Biosystems 2006, Lexington (United States), Public	Developer of miniaturized MRI platforms for clinical diagnostics	$454M	Polaris Partners, Flagship Pioneering & 20 others	55/100
207th	Gradian 2018, Austria, Seed	Developer of molecular diagnostic devices for the identification of infectious diseases	$99.2K	-	25/100